Yuhan’s Leclaza targets US mkt based on its clinical effect
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.09.02 05:45:58
가나다라
0
Reaffirmed efficacy of Leclaza... Expected to target the market with the ‘Ryvrevant+Leclaza’ combo
Positive OS trend compared with Tagrisso...at 31.1 months of follow-up, 44% of patients on Leclaza continued treatment
The non-small cell lung cancer drug Leclaza (lasertinib) in combination with Ryvrevant(amivantamab) has gained competitivity in the U.S., based on data presented at the World Congress on Lung Cancer (WCLC 2024).
Additional data on Leclaza monotherapy and Leclaza in combination with Ryvrevantare is expected to be presented to further increase the drug’s clinical value.
▲ WCLC 2024 will be held from September 7 in San Diego, U.S.
According to industry sources on the 31st, results from a study comparing the efficacy and safety of Leclaza+Ryvrevant and Leclaza monotherapy to Tagrisso monotherapy will be presented at WCLC 2024, which will be held from September 7 in San Diego, U.S.
The data to be presented at WCLC 2024 are from
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)